Sema4 provided revenue guidance for the year 2022. The company expects total revenue for fiscal year 2022 to be in the range of $215 million to $225 million, implying 23-29% growth excluding revenue associated with COVID-19, and Sema4 also expects to result over 350,000 tests in 2022 excluding COVID-19 tests.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
19.52 USD | -0.71% | +77.45% | +609.82% |
04-30 | Health Care Flat Amid Mixed Earnings -- Health Care Roundup | DJ |
04-30 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+609.82% | 514M | |
-17.86% | 8.3B | |
+49.55% | 3.78B | |
-8.23% | 2.47B | |
-34.62% | 2.46B | |
-9.24% | 2.31B | |
-4.14% | 1.95B | |
-17.46% | 1.59B | |
-37.88% | 1.21B | |
+8.08% | 1.1B |
- Stock Market
- Equities
- WGS Stock
- News GeneDx Holdings Corp.
- Sema4 Provides Revenue Guidance for the Year 2022